

ORYZON to Present Clinical Data on LSD1 Inhibitor ORY-1001 at ASH 2016

**Investor / analyst luncheon event on ORY-1001 to be held
Monday, December 5th**

BARCELONA, SPAIN and CAMBRIDGE, MA, November 14th, 2016 – Oryzon Genomics (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today announced that the Company will present preliminary safety and efficacy clinical data of its investigational drug ORY-1001, a LSD1 selective inhibitor, at a poster session at the American Society of Hematology (ASH) 58th Annual Meeting and Exposition, being held December 3-6, 2016 in San Diego, California.

Investor / Analyst Luncheon

Oryzon will host an investor and analyst luncheon on Monday, December 5, 2016 at 12:30 PM -1:30 PM PST at the San Diego Marriott Gaslamp Quarter Hotel. Management, investigators Tim Somerville (The Christie NHS Foundation Trust) and Francesc Bosch (University Hospital Vall d'Hebron), and Roche representative Gwen Nichols (Roche Translational Clinical Research Center) will discuss ORY-1001 Phase I/IIA data in Acute Myeloid Leukemia. The luncheon will be webcast, and an archived version of the webcast will be available for replay following the event and can be accessed on the Oryzn website.

Poster Information

Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Preliminary Activity in Acute Leukemia of Ory-1001, a First-in-Class Inhibitor of Lysine-Specific Histone Demethylase 1A (LSD1/KDM1A): Initial Results from a First-in-Human Phase 1 Study

Abstract Number: 4060

Session Name: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster III

Date: Monday, December 5, 2016

Presentation Time: 6:00 PM - 8:00 PM PST

Location: Hall GH (San Diego Convention Center)

The abstract is available on the official website of ASH-2016 Conference <https://ash.confex.com/ash/2016/webprogram/Paper93141.html>.

About ORY 1001

ORY-1001 (RG6016), Oryzon's first clinical asset, is a highly potent and selective Lysine Specific Demethylase-1 (LSD1) inhibitor for the treatment of leukemia and other malignancies, currently in Phase I/IIA in Acute leukemia, that was partnered with Roche in a global deal in 2014. Beyond hematological malignancies, LSD1 inhibition has been proposed as a valid therapeutic approach in some solid tumors such as Small cell lung cancer (SCLC). SCLC represents 15% of lung neoplasms and is an aggressive malignancy with limited treatment options. Survival in refractory settings is typically less than one year, exemplifying the need for more effective therapeutics. Recent published results suggest that epigenetic modulation mediated by LSD1 inhibition may be effective to treat SCLC.

About Oryzon

Founded in 2000 in Barcelona, Spain, Oryzon (ISIN Code: ES0167733015) is a clinical stage biopharmaceutical company considered as the European champion in Epigenetics. The company has one of the strongest portfolios in the field and a clinical asset already partnered with Roche. Oryzon's LSD1 program is currently covered by +20 patent families and has rendered two compounds in clinical trials. In addition, Oryzon has ongoing programs for developing inhibitors against other epigenetic targets. The company has a strong technological platform for biomarker identification and performs biomarker and target validation for a variety of malignant and neurodegenerative diseases. Oryzon's strategy is to develop first in class compounds against novel epigenetic targets through Phase II clinical trials, at which point it is decided on a case-by-case basis to either keep the development in-house or to partner or outlicense the compound for late stage development and commercialization. The company has offices in Barcelona and Cambridge, Massachusetts. For more information, visit www.oryzon.com.

FORWARD-LOOKING STATEMENTS

This communication contains forward-looking information and statements about Oryzon Genomics, S.A., including financial projections and estimates and their underlying assumptions, statements regarding plans, objectives and expectations with respect to future operations, capital expenditures, synergies, products and services, and statements regarding future performance. Forward-looking statements are statements that are not historical facts and are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates" and similar expressions. Although Oryzon Genomics, S.A. believes that the expectations reflected in such forward-looking statements are reasonable, investors and holders of Oryzon Genomics, S.A. shares are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Oryzon Genomics, S.A., that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include those discussed or identified in the documents sent by Oryzon Genomics, S.A. to the *Comisión Nacional del Mercado de Valores*, which are accessible to the public. Forward-looking statements are not guarantees of future performance. The auditors of Oryzon Genomics, S.A. have not reviewed them. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date they were made. All subsequent oral or written forward-looking statements attributable to Oryzon Genomics, S.A. or any of its members, directors, officers, employees or any persons acting on its behalf are expressly qualified in their entirety by the cautionary statement above. All forward-looking statements included herein are based on information available to Oryzon Genomics, S.A. on the date hereof. Except as required by applicable law, Oryzon Genomics, S.A. does not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

ORYZON

*Epigenetic drugs
for a better world*

PRESS RELEASE 2016

US Contact:

The Trout Group

Maria Lomaka

+1 646 378 2932

mlomaka@troutgroup.com

Spain:

ATREVIA

Patricia Cobo/Luis Rejano

+34 91 564 07 25

pcobo@atrevia.com

lrejano@atrevia.com

The Company:

Anna K Baran

IR Director

+44 (0) 752 1083 006

abaran@oryzon.com